Every 424B that bioAffinity Technologies, Inc. (BIAF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BIAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAF filings page.
bioAffinity Technologies is offering 1,040,000 shares of common stock at $0.80 per share and registering up to 2,960,000 pre-funded warrants exercisable at $0.007 to prevent purchasers exceeding 4.99% (or 9.99% by election) ownership. The prospectus states estimated net proceeds of approximately $2.6 million and a Placement Agent fee of 7.5%.
The offering includes Placement Agent Warrants equal to 3.0% of shares sold at an exercise price of $0.88. Shares outstanding were 4,743,061 as of June 16, 2026, and would be 8,743,061 assuming full exercise of pre-funded warrants sold hereunder.
bioAffinity Technologies, Inc. is registering 497,483 shares of Common Stock for resale by selling stockholders pursuant to this prospectus. The shares comprise 365,603 Warrant Shares issuable upon anti-dilution adjustments to outstanding warrants and 131,880 Conversion Shares issuable upon anti-dilution adjustments to Series B Convertible Preferred Stock.
The company is not offering any shares for its own account and will not receive proceeds from resales by the selling stockholders; the company would receive cash only if the related Warrants are exercised for cash. Share counts in this prospectus assume conversion/exercise for resale purposes and state 4,498,675 shares outstanding as of December 31, 2025, rising to 4,996,155 shares after the offering per the offering table.
bioAffinity Technologies, Inc. filed a prospectus supplement describing a common stock offering at an offering price of $0.20 per share. The placement agent fees are $144,000.00, and the proceeds, before expenses, are $1,656,000.00. The document shows a historical net tangible book value per share of $(4.52) as of June 30, 2025, a pro forma net tangible book value per share of $0.20, and a pro forma as adjusted net tangible book value per share of $1.34, representing an $0.15 increase attributable to the offering. The disclosure also reports dilution per share to the new investor of $1.19 and lists authorized capital of 25,000,000 common shares (par value $0.007) and 20,000,000 preferred shares (par value $0.001).
bioAffinity Technologies, Inc. (BIAF) prospectus excerpts show a public offering priced at $2.50 per share with placement agent fees of $0.20 per share, producing proceeds before expenses of $2.30 per share and aggregate proceeds of $4,414,421.31. Historical net tangible book value per share was $0.20; the pro forma increase attributable to the offering is $0.99, producing a pro forma as-adjusted net tangible book value per share of $1.19. The filing notes Total capitalization of $(2,136,108) and references shares issuable upon conversion of 715.5 Series B Convertible Preferred shares at an initial conversion price of $6.90 per share.